Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.95 USD | +1.21% | +1.27% | +12.96% |
Financials (USD)
Sales 2024 * | 168M | Sales 2025 * | 299M | Capitalization | 1.53B |
---|---|---|---|---|---|
Net income 2024 * | -48M | Net income 2025 * | 58M | EV / Sales 2024 * | 8.99 x |
Net cash position 2024 * | 19.66M | Net cash position 2025 * | 70.24M | EV / Sales 2025 * | 4.89 x |
P/E ratio 2024 * |
-28.8
x | P/E ratio 2025 * |
26.6
x | Employees | 154 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.29% |
Latest transcript on Avadel Pharmaceuticals plc
1 day | +1.21% | ||
1 week | +1.27% | ||
1 month | -12.89% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Thomas McHugh
DFI | Director of Finance/CFO | 59 | 19-12-01 |
Scott Macke
COO | Chief Operating Officer | - | 14-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Ende
BRD | Director/Board Member | 55 | 18-11-30 |
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Mark McCamish
BRD | Director/Board Member | 72 | 19-12-04 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 15.95 | +1.21% | 738,608 |
24-05-30 | 15.76 | +1.09% | 1,100,938 |
24-05-29 | 15.59 | +0.65% | 469,231 |
24-05-28 | 15.49 | -1.65% | 812,393 |
24-05-24 | 15.75 | +0.83% | 642,350 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.96% | 1.53B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- AVDL Stock